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Abstract
Background: Cardiovascular disease (CVD) is a leading cause of mortality in the United States as well as globally.
Epidemiological studies show that regular fruit and vegetable consumption reduces CVD risk, in part, due to
antioxidant activity and immunomodulation since oxidative stress and inflammation are features of atherogenesis.
Accumulating evidence also shows that dietary fungi, viz., mushrooms, can protect against chronic disease by
altering inflammatory environments such as those associated with CVD although most research has focused on
specialty mushrooms. In this study, we tested the ability of both common and specialty mushrooms to inhibit
cellular processes associated with CVD.
Methods: Human aortic endothelial cells (HAEC) were incubated overnight with control media with
dimethylsulfoxide (DMSO) vehicle (1% v/v) or containing DMSO extracts of whole dehydrated mushrooms (0.1 mg/
mL), which included Agaricus bisporus (white button and crimini), Lentinula edodes (shiitake), Pleurotus ostreatus
(oyster), and Grifola frondosa (maitake). Monolayers were subsequently washed and incubated with medium alone
or containing the pro-inflammatory cytokine IL-1b (5 ng/mL) for 6 h to upregulate pro-atherosclerotic adhesion
molecules (AM). AM expression was assayed by ELISA and binding of U937 human monocytes pre-loaded with
fluorescent dye was determined.
Results: White button mushrooms consistently reduced (p < 0.05) VCAM-1, ICAM-1, and E-selectin-1 expression,
whereas other test mushrooms significantly modulated AM expression singly, collectively, or combinatorially. All
mushrooms, however, significantly reduced binding of monocytes to both quiescent and cytokine-stimulated
monolayers.
Conclusion: These data provide evidence that dietary mushrooms can inhibit cellular processes such as adhesion
molecule expression and ultimate binding of monocytes to the endothelium under pro-inflammatory conditions,
which are associated with CVD. As a result, these findings support the notion that dietary mushrooms can be
protective against CVD.
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Cardiovascular disease (CVD) is a leading cause of mor-
bidity and mortality in the United States as well as glob-
ally in both developed and developing countries [1].
Epidemiological studies show that regular consumption
of plants, i.e., fruits and vegetables, is strongly and con-
vincingly associated with a reduced risk of chronic dis-
ease including CVD [2,3]. This protection presumably
occurs due to a plethora of bioactive phytochemicals
that can modulate processes including the immune
response, inflammation and antioxidant activity [4,5]. In
addition to plants, dietary fungi, viz., mushrooms, also
contain a diverse array of biologically active molecules
rendering them potentially protective against CVD [6,7].
In fact, dietary mushrooms have been shown in previous
studies to improve cardiovascular health, stimulate
immune function, contribute to glucose homeostasis,
and to modulate detoxification, as well as exert anti-
allergic, anti-tumor, anti-viral, antibacterial, antifungal,
and anti-inflammatory activities [5,8-10]. As a result,
both cellular components and secondary metabolites of
myriad dietary mushrooms have been used in treatment
for a variety of diseases [11]. While previous results
have been compelling, research has largely focused on
specialty or exotic mushrooms associated with the Far
East including shiitake, maitake, and reishi. However,
the white button mushroom is the most frequently con-
sumed mushroom in the United States and could be
equally effective in preventing or slowing CVD [10].
The etiology of CVD involves, in part, a complex pro-
cess of development and deposition of cholesterol-
ladened fatty streaks within aortic blood vessels and
appears associated with oxidative stress and inflamma-
tion [12,13]. Accumulating evidence suggests also a cri-
tical link between inflammation and metabolic
syndrome, CVD, and diabetes [14]. Pro-inflammatory
cytokines such as IL-1b, chemokines, and upregulation
of several key adhesion molecules including intercellular
adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1), and endothelial-leukocyte adhe-
sion molecule-1 (ELAM-1 or E-selectin) have been
shown to contribute significantly to CVD by initiating
an interaction between the vascular endothelium and
monocytes, precursors to foam-ladened macrophages
[13,15]. The increased expression of adhesion molecules,
migration of monocytes into the aortic subendothelium,
and foam cell formation can contribute to atherosclero-
tic plaque development and premature cardiovascular
disease and death. It has been demonstrated that an
atherogenic diet high in dietary fat such as the Western
diet can also rapidly induce adhesion molecules and
contribute to atherogenesis [16]. Some dietary agents,
such as mushrooms, can inhibit or attenuate these
processes, which would be beneficial in slowing or pre-
venting downstream chronic disease.
Despite emerging evidence, little attention has been
focused on the potential protective role of edible mush-
rooms against atherogenesis in a biological context or
determination of a specific underlying mechanism.
Moreover, a lingering question is whether common
dietary mushrooms can be as effective as specialty, or
exotic, mushrooms. In this research, we have deter-
mined whether both common mushrooms and specialty
mushrooms can modulate critical events leading to
atherogenesis such as pro-inflammatory, cytokine-
induced upregulation of adhesion molecule expression
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selected as test mushrooms Agaricus bisporus (white
button and crimini varieties), Lentinula edodes (shii-
take), Pleurotus osteratus (oyster), and Grifola frondosa
(maitake). After analyzing VCAM-1, ICAM-1, and E-
selectin expression, we assessed whether significant
reductions in binding of human monocytes to aortic
endothelium in a quiescent or a pro-inflammatory
environment occurred. We hypothesized that preincuba-
tion of human aortic endothelial cells (HAEC) with
dimethylsulfoxide (DMSO) extracts of whole mush-
rooms would inhibit the adverse binding of U937
human monocytes to cytokine-stimulated aortic
endothelium using an in vitro model of atherogenesis.
Methods
Preparation and delivery of mushrooms
Samples of mushrooms were collected from The Penn-
sylvania State University Mushroom Test Demonstration
Facility and Mushroom Research Center and Modern
Mushroom Farm, Inc. (Toughkennamon, PA) as out-
lined in Table 1. Mushrooms were grown using the
standard tray system under controlled conditions and
were harvested at the optimum maturation stage with
closed caps that were 2.0-2.5 inches in diameter [17].
Mushrooms from the second break of the A. bisporus
Table 1 Mushrooms selected for testing
Test
Mushroom
Genus/Species Sample type Source
Shiitake Lentinula
edodes
Basidioma Modern Mushroom
Farm
Crimini Agaricus
bisporus
brown
mushroom
Penn State University
Oyster Pleurotus
ostreatus
Basidioma Modern Mushroom
Farm
Maitake Grifola frondosa Basidioma Modern Mushroom
Farm
White Button Agaricus
bisporus
all crops Penn State University
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rooms and the common white button mushrooms. Spe-
cialty mushrooms were harvested using standard
mycology protocols and harvested on peak production
days [17].
Harvested mushroom crops were randomly sampled,
cleaned, sliced, and stored at 0°C for 24 h. Samples were
later freeze-dried (Model 15 SRC-X; Virtis Genesis Co,
Inc., Gardiner, NY), ground to a fine powder, and sieved
through a 16 mesh screen. Mushroom powders were
collected in sterile sample bags (Fisher Scientific, Pitts-
burgh, PA) and stored in the dark at room temperature
in desiccators prior to analysis.
After analyses, lyophilized mushroom powders were
stored desiccated at -80°C in the dark until use. Stock
solutions of each test mushroom were prepared by dis-
solving 100 mg mushroom powder into 10 mL DMSO
(Sigma, St. Louis, MO) in tubes immersed in ice fol-
lowed by three cycles of 2 min each of sonication
using a Bransonic sonifier (Model S450, Danbury, CT).
Immediately prior to experiments, aliquots of stock
solutions (0.01 mL) were independently diluted into
endothelial cell basal medium (EBM) medium to pro-
duce 0.1 mg/mL working concentrations each with 1%
(v/v) DMSO. DMSO was not toxic at this concentra-
tion as determined by viability assays when compared
to control cultures with medium alone (data not
shown).
Cell culture
HAEC were purchased from Clonetics Laboratories
(San Diego, CA) and cultured in EBM (Clonetics, San
Diego, CA). The medium contained 10% fetal bovine
serum (FBS), hydrocortisone, vascular endothelial
growth factor, insulin-like growth factor, fibroblast
growth factor, gentamicin, epidermal growth factor,
heparin, and ascorbic acid at concentrations provided
as a kit by the manufacturer (Clonetics, San Diego,
CA). HAEC were seeded in 1% gelatin (Sigma, St.
Louis, MO) coated Corning T-75 flasks, 24, and 96-
well plates (Corning, NY). Medium was changed every
other day and cells were subcultured by trypsinization,
resuspension, and reseeding to flasks to propagate cul-
tures. For experiments, HAEC were used for three pas-
sages (number of times subcultured) since they are
non-transformed and non-immortalized. For this study,
cells were grown to confluence and each assay was
replicated 3-4 times in quadruplicate using passages
6-8. U-937 monocytes (ATCC, Rockville, MD) grew in
suspension culture in RPMI-1640 medium (Sigma, St.
Louis, MO) supplemented with 10% FBS, 2 mM gluta-
mine, 100 U/mL penicillin, and 100 ug/mL streptomy-
cin. Medium was exchanged every 3 d and cells were
subcultured weekly.
Cytotoxicity of mushroom powders
Monolayers of HAEC were incubated overnight with
media containing DMSO vehicle alone (1% v/v) or con-
taining the test mushroom powders. Cytotoxicity was
determined by changes in morphology as determined by
light microscopy and trypan blue exclusion as an indica-
tor of viability.
Adhesion molecule expression
HAEC were cultured in 24-well plates until confluent
and were incubated overnight with mushroom powders
dissolved in cell culture medium as described above.
After incubation, monolayers were washed twice with
phosphate buffered saline (PBS) (0.5 mL/well) and
further incubated with medium alone or with IL-1b
(5 ng/mL) for 6 h at 37°C. Medium was removed and
monolayers were fixed with 1% formaldehyde at 25°C
for 30 min. Monolayers were washed with PBS and
blocked with 10% FBS in PBS for 1 h to reduce non-
specific binding and background. Monoclonal antibodies
against human VCAM-1, ICAM-1, and E-selectin (BD
Pharmingen, San Diego, CA) were added at 5, 1, and
10 μg/mL, respectively, in PBS with 10% FBS for 1 h at
25°C. The secondary antibody, horseradish-conjugated
anti-mouse IgG (Santa Cruz, CA), was added at a 1:400
dilution and incubated at 25°C for 2 h. Subsequently
and after washing with PBS, horseradish peroxidase sub-
strate was added and cells were incubated for 1 h to
develop the colorimetric endpoint (Bio-Rad, Hercules,
CA). The optical densities, or absorbances, were read at
405 nm using a Tecan SpectraFluor multi-well plate
reader (Tecan, Research Triangle Park, NC).
Fluorescent labeling of monocytes
U-937 cells (ATCC, Rockville, MD), a human monocyte
cell line, was used to test adherence to HAEC monolayer
[18]. Prior to co-incubation, U-937 cells were fluores-
cently labeled by incubating cells (2 × 10
6 cell/mL) with
5 μM BCECF-AM/L [2’,7 ’-bis-(2-carboxyethyl)-5 (and
6)-carboxy-fluorescent acetoxymethyl ester] (Molecular
Probes, Eugene, OR) in EBM medium for 30 min at 37°C
and 5% CO2 as described previously [19]. BCECF-AM, a
non-fluorescent lipophilic compound, readily enters cells
where it is modified to become fluorescent and retained
by cells. BCECF-AM was prepared as a 1 mg/mL stock in
DMSO and stored at -80°C. After labeling, cells were
washed twice with PBS containing 1% FBS to remove
excess dye. U937 cells were then resuspended in medium
(5 × 10
5 cells/mL) and added (0.5 mL/well) to HAEC
monolayers as described below.
U-937 monocyte binding to HAEC
HAEC were cultured in gel-coated 24-well plates until
confluent then incubated overnight with mushroom
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above. After incubation, monolayers were washed twice
with PBS (0.5 mL/well) and further incubated with
IL-1b (5 ng/mL) for 6 h at 37°C. U-937 cells, labeled as
described above, were incubated with HAEC for 30 min
at 37°C and 5% CO2. After incubation, non-adherent
cells were removed by washing twice with PBS contain-
ing 1% FBS. The attached cells were lysed with 0.5 mL
of 50 mM Tris buffer (pH 7.6) containing 1% sodium
dodecyl sulfate (SDS). The fluorescent intensity was
measured at excitation and emission wavelengths of 485
and 535 nm, respectively, with a Tecan Spectrafluor
fluoresence multiwell plate reader.
Statistical analysis
Data were analyzed using the Students t test to compare
individual treatment groups with the respective controls.
Values are displayed as means + SEM and p < 0.05 is
considered significant.
Results
VCAM-1 expression
Increased expression of adhesion molecules and binding
of monocytes to HAEC are critical events in atherogen-
esis. As a result, we first analyzed the expression of
VCAM-1 after pre-incubation with medium alone or
containing mushroom powder. After stimulation with IL-
1b for 6 h, VCAM-1 expression significantly increased by
3.8 fold in DMSO vehicle control cells (Fig. 1). There
were no differences between stimulated DMSO vehicle-
treated cells and stimulated cells incubated with medium
alone. After preincubation with mushrooms, VCAM-1
expression was marginally, but significantly, reduced by
24.8 amd 10.5% after crimini and white button mush-
room powder, respectively. Basal expression of VCAM-1
was not significantly altered after pre-incubation with
mushrooms.
ICAM-1 expression
We next analyzed the expression of the adhesion mole-
cule ICAM-1. Basal ICAM-1 expression was higher than
either basal VCAM-1 or E-selectin as observed pre-
viously and routinely and was not altered by pre-incuba-
tion with solutions from mushroom powder. Incubation
with IL-1b increased significantly ICAM-1 expression by
2-fold as expected (Fig. 2). After pre-incubating with
mushroom extracts, ICAM-1 expression was marginally,
but significantly, decreased by white button mushroom
powder by 8%. Other test mushrooms did not signifi-
cantly reduce ICAM-1 adhesion molecule expression.
E-selectin expression
We next analyzed the expression of the adhesion mole-
cule E-selectin. Basal expression remained low and
unchanged in all cultures including treatment groups
(Fig. 3). After incubation with IL-1b,E - s e l e c t i n
Figure 1 VCAM-1 adhesion molecule expression in HAEC. Monolayers were incubated overnight with 1% (v/v) DMSO alone (DMSO) or with
mushroom powder (0.1 mg/mL) including shiitake (S), crimini (C), oyster (O), maitake (M), and white button (WB). Cell monolayers were washed
then incubated with medium alone or IL-1b (5 ng/mL) for 6 h. After harvesting, VCAM-1 expression was determined by ELISA. Data indicate
mean optical density (O.D.) ± SEM and are representative of 3-4 experiments each performed in quadruplicate. *p < 0.05 vs. control.
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Page 4 of 9Figure 2 ICAM-1 adhesion molecule expression in HAEC. Monolayers were incubated overnight with 1% (v/v) DMSO alone (DMSO) or with
mushroom powder (0.1 mg/mL) including shiitake (S), crimini (C), oyster (O), maitake (M), and white button (WB). Cell monolayers were then
washed and incubated with medium alone or IL-1b (5 ng/mL) for 6 h. After harvesting, ICAM-1 expression was determined by ELISA. Data
indicate mean optical density (O.D.) ± SEM and are respresentative of 3-4 experiments each performed in quadruplicate. *p < 0.05
vs. control.
Figure 3 E-selectin adhesion molecule expression in HAEC. Monolayers were incubated overnight with 1% (v/v) DMSO alone (DMSO) or
with mushroom powder (0.1 mg/mL) including shiitake (S), crimini (C), oyster (O), maitake (M), and white button (WB). Cell monolayers were
washed then incubated with medium alone or IL-1b (5 ng/mL) for 6 h. After harvesting, E-selectin expression was determined by ELISA. Data
indicate mean optical density (O.D.) ± SEM and are representative of 3-4 experiments each performed in quadruplicate. *p < 0.05
vs. control.
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incubation with mushrooms, E-selectin expression was
significantly reduced by 8, 20, 18, 13, and 14% after pre-
incubation with shiitake, crimini, oyster, maitake, and
white button mushroom powders, respectively.
Binding of U937 monocytes
We next analyzed the capacity for pre-loaded U937
monocytes to bind and adhere to human aortic
endothelial cells. Pre-incubation with mushrooms
reduced adhesion of monocytes to unstimulated HAEC
significantly by 23, 44, 50, 55, and 60% for shiitake,
crimini, oyster, maitake, and white button mushroom
powders, respectively (Fig. 4). Incubation with IL-1b sig-
nificantly increased monocyte adherence to HAEC by
2.7-fold (Fig. 4). Pre-incubation with crimini, oyster,
maitake, and white button significantly reduced U937
adhesion to IL-1b-stimulated HAEC by 18, 18, 16, and
26%, respectively. Pre-incubation with shiitake was not
different from control cultures and did not affect bind-
ing of monocytes.
Discussion
T h i ss t u d yi st h ef i r s tt od e m o n s t r a t et h ec a p a c i t yo f
whole mushrooms, delivered as DMSO extracts, to
reduce adhesion molecule expression with subsequent
reductions in human monocyte binding to human aortic
endothelial cells. Specifically, we have demonstrated that
dietary mushrooms significantly reduced cell surface
expression of VCAM-1, ICAM-1, and E-selectin.
Furthermore, there were significant reductions in
adhesion of pre-loaded human monocytes to both unsti-
mulated, or quiescent, and pro-inflammatory, cytokine-
stimulated HAEC as summarized in Table 2. The health
implications are that diverse mushrooms, including
common and specialty mushrooms can protect against
cardiovascular disease by interfering with events that
contribute to atherogenesis.
Figure 4 Binding of U937 human monocytes to HAEC. HAEC monolayers were incubated overnight with 1% (v/v) DMSO alone (DMSO) or
with mushroom powder (0.1 mg/mL) including shiitake (S), crimini (C), oyster (O), maitake (M), and white button (WB). Monolayers were washed
then incubated with medium alone or containing IL-1b (5 ng/mL) for 6 h. After washing again to remove IL-1b, fluorescently labeled U937 cells
were co-incubated with HAEC for 30 min at 37°C. HAEC monolayers and bound U937 cells were harvested and the total fluorescence was
analyzed to determine monocyte binding. Data indicate mean relative fluorescent units (RFU) ± SEM and are resentative of 3-4 experiments each
performed in triplicate. *p < 0.05 vs. control.
Table 2 Summary of effects by mushrooms on adhesion molecule expression and monocyte binding
Mushroom VCAM-1 ICAM-1 E-selectin Binding-U* % Binding-S %
Shiitake reduced reduced 23 no change 0
Crimini reduced reduced reduced 44 reduced 18
Oyster reduced reduced 50 reduced 18
Maitake reduced reduced 55 reduced 16
White button reduced reduced reduced reduced 60 reduced 26
*U, unstimulated HAEC cells; S, stimulated with IL-1b.
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ing their potential role in protecting against cardiovas-
cular disease although studies have suggested a
protective effect against CVD. For example, powders
(5% dry weight) of shiitake, maitake, and Agaricus bis-
porus significantly decreased plasma cholesterol levels
and blood pressure in rats presumably due to the bioac-
tive agent eritadenine [20-22]. Furthermore, dietary
oyster mushrooms (P. ostreatum)a l s oe l i c i t e dah y p o -
cholesterolemic effect and inhibited lipid peroxidation, a
process linked to oxidative stress, in rabbits [23,24].
This is in agreement with our results in that white but-
ton and crimini (A. bisporus), maitake and oyster signifi-
cantly reduced AM expression and monocyte binding,
which would counter a hypercholesterolemic, or hyperli-
pidemic, effect. That is, even with elevated plasma levels
of lipids, the reduced expression of AM and subsequent
inhibition of binding of monocytes would interrupt the
atherogenic process. This is further supported by the
observation that a 10% (w/w) oyster mushroom diet sig-
nificantly reduced both the incidence and size of aortic
atherosclerotic plaques in rabbits suggesting interaction
with physiological and molecular processes of athero-
genesis [23,24]. Percario et al. also showed that a natural
antioxidant-rich mushroom, Agaricus sylvaticus,c o u l d
prevent the development of atherosclerosis in an envir-
onment of hypercholesterolemia using a rabbit model
[25]. Collectively, several studies suggest that dietary
mushrooms can inhibit or slow CVD although more
research is needed.
In this report, we have demonstrated that both com-
mon and specialty mushrooms can modulate processes
at the cellular level where AM expression is attenuated
and binding of monocytes blunted. Others have identi-
fied alternative mechanisms for a potential CVD protec-
tive effect by dietary mushrooms. For example, oyster
mushrooms (10% of diet) reduced significantly the inci-
dence of atherosclerotic plaques in rabbits as well as
plaque size by 26% compared to the control group and
prevented formation of atheromas, reduced foam cell
number, and reduced coronary arterial injury [24].
Other dietary antioxidants (vitamins C, E, and beta caro-
tene) have been shown to reduce lesion area by reducing
concentrations of soluble adhesion molecules by 36-61%
in mice [26]. This observation is important because
soluble AM have been proposed as a critical assessment
tool for asymptomatic CVD in high-risk patients [27].
While we did not measure soluble AM in this study, the
capacity of the test mushrooms to reduce cell surface
expression in HAEC is equally compelling as a protec-
tive mechanism. Other proposed mechanisms of cardio-
protection in rodents consuming Grifola frondosa,
Inonotus obliquus, Antrodia xantha,a n dRigidoporus
ulmarius include inhibition of COX-1 and COX-2
activities, inhibition of iNOS via reduced NF-kB binding,
and potent antiangiogenesis activity [28-30]. Collectively,
the data support the capacity of both exotic and com-
monly consumed mushrooms to beneficially modulate
numerous processes associated with atherogenesis.
We also noted in this study that the three most fre-
quently measured AM including VCAM-1, ICAM-1 and
E-selectin, were reduced singly, collectively, or in various
combinations of two after incubation with mushrooms
yet binding of monocytes was consistently reduced after
incubation with each mushroom extract. Others have
shown similar results with different dietary agents using
the HAEC cell model, which is a non-transformed pri-
mary endothelial cell line. For example, pretreatment of
HAEC with a red wine polyphenol extract significantly
inhibited oxysterol-induced cell surface expression of
adhesion molecules and subsequent adherence of mono-
cytes to monolayers by inhibiting primarily VCAM-1
[31]. Subsequent studies by Naito et al. showed that
tocotrienols exerted a similar effect [32]. Dietary con-
sumption of antioxidant polyphenols from avenathra-
mide-enriched mixtures (AEM) derived from oats
significantly reduced IL-1b-stimulated VCAM-1, ICAM-
1, and E-selectin expression in HAEC by 50, 20, and
20% respectively, and reduced U937 binding at concen-
trations as low as 20 μg/mL [33]. Ginkgo biloba extracts
reduced both VCAM-1 and ICAM-1 and adhesion of
monocytes to HAEC [34]. In a study using structurally
related dietary carotenoids, Martin et al. found that pre-
incubation of HAEC with beta-carotene, lutein and lyco-
pene significantly reduced VCAM-1 expression, beta-
carotene and lutein significantly reduced E-selectin
expression, and beta-carotene, lutein and lycopene sig-
nificantly reduced the expression of ICAM-1, yet lyco-
pene was the only carotenoid to significantly reduce
binding of U937 to HAEC [19]. The antioxidant pyrroli-
dine dithiocarbamate selectively inhibited in HUVEC
cells VCAM-1 induction, but not ICAM-1, after stimula-
tion with TNF-a and LPS. E-selectin was only partially
inhibited after TNF-a incubation [35]. Pretreatment of
HUVECs with vitamin E and probucol significantly
reduced the expression of VCAM-1 induced by oxidized
LDL, but did not reduce expression of ICAM-1 [36]. In
contrast, the well recognized antioxidants N-acetyl-L-
cysteine and troglitazone, an antidiabetic agent, reduced
or completely abolished VCAM-1, E-selectin, and
ICAM-1 expression in endothelial cells after pro-oxidant
signals including oxidized LDL and TNF-a [37]. Thus,
each of the three commonly tested AM can be modu-
lated either singly or in combination by diverse dietary
agents and typically at least one, but often more, are
inhibited. This suggests thata t t e n u a t i o no fa tl e a s to n e
AM, without specificity as to which one, may be ade-
quate for inhibition of binding of monocytes but also
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that may not be measured.
It is noteworthy that mushrooms also contain high
levels of bioactive agents including polyphenols and the
novel antioxidant ergothioneine, which is produced
exclusively in mushrooms and some bacteria [38,39].
Dietary polyphenols such as catechin and quercetin have
been shown to significantly reduce VCAM-1 expression
and binding of monocytes to HAEC and ergothioneine
exerts antioxidant activity that may be protective in a
pro-inflammatory environment [40-42]. The test mush-
rooms used in this study have been analyzed and found
to contain considerable amounts of both ergothioneine
and total polyphenols [43,44]. Moreover, all test mush-
rooms exhibited significant antioxidant capacities using
assays for oxygen radical absorbance capacity (ORAC),
and hydroxyl (HORAC), peroxynitrite (NORAC), and
superoxide (SORAC) radical averting capacity. Mush-
rooms also contain high levels of selenium and copper,
essential micronutrients, needed for proper function of
antioxidant enzymes, which can reduce oxidative stress
and inflammation often found in CVD [45]. It is possi-
ble that varying levels of these bioactive agents alone or
in combination contributed to the beneficial effects
observed.
Conclusions
In conclusion, dietary mushrooms sampled from both
common, which are routinely consumed in the United
States, and specialty mushrooms interfered with pro-
cesses critical to atherogenesis and cardiovascular dis-
ease. These findings further support the notion that
consumption of not only fruits and vegetables, but also
dietary fungi, viz., mushrooms, is an important approach
to minimizing CVD risk. Moreover, common, readily
available and affordable mushrooms such as white but-
ton, or Agaricus bisporus, as well as specialty mushrooms
including shiitake appear particularly beneficial to health.
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